BioCryst Pharmaceuticals (BCRX): Investors Reward Forecast Increase with Stock Rise to a 52-Week High!
Reading Time: 1 minute
BioCryst Pharmaceuticals Inc. (BCRX) (i.) has smashed expert expectations with its first-quarter numbers released on May 5. The key driver was strong demand for ORLADEYO, containing the active ingredient Berotralstat, which can be used to prevent swelling attacks in people with hereditary angioedema (HAE). HAE causes recurrent painful and sometimes life-threatening swelling, for instance in the face, neck, abdomen, or extremities. As demand is expected to continue increasing, the company has also raised its annual forecast. The company now anticipates...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
